Our study revealed SNORA13 is highly expressed in CRC and demonstrated knockdown of SNORA13, especially combined with 5-FU administration, may represent a promising therapeutic approach for CRC treatment. This evidence concerns the gene SNORA13 and colorectal carcinoma.